NICE
Gilead expands UK presence with new London HQ
February 10, 2015Research and Development, Sales and Marketing Cambridge, Gilead, London, NICE, UK, johnson, medcity, sovaldi, uxbridge
Gilead is to create a new UK commercial secondary headquarters in central London doubling its UK workforce to 600 by …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
NICE approves world’s most expensive drug
January 28, 2015Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris
The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
CDF chair: more treatment reviews to come
January 16, 2015Sales and Marketing CDF, Cancer Drugs Fund, NHS, NHS England, NICE, peter clark
The chair of NHS England’s cancer drugs fund has said there is likely to be more reviews of affordable treatments …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
NICE releases reflux disease guidelines
January 15, 2015Sales and Marketing NHS, NICE, UK, gor, gord, h2ra
NICE has released new guidelines providing doctors with advice on how to treat gastro-oesophageal reflux disease (GORD) in young people. …
Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
NICE rejects Takeda Crohn’s disease drug
December 23, 2014Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab
Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
Latest content
FibroFind appoints Lee Borthwick as CEO
